Search for Clinical Trial Results

Sponsored By

Perivascular Epithelioid Cell Neoplasms - 25 Studies Found

Status Study
Recruiting Study Name: A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa
Condition: PEComa
Date: 2015-07-08
Interventions: Drug: ABI-009
Withdrawn Study Name: A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa
Condition: Malignant PEComa (Perivascular Epithelioid Cell Tumors)
Date: 2012-09-06
Interventions: Drug: BEZ235 Patients will be provided with an adequate supply of study treatment for self-administratio
Completed Study Name: Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors
Condition:
  • PEComa
  • Hemangioma

Date: 2014-12-22
Interventions: Other: Biopsy
Not yet recruiting Study Name: Trabectedin Maintenance Post 1st-line in STS
Condition: Sarcoma, Soft Tissue
Date: 2016-10-07
Interventions: Drug: Trabectedin Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24
Recruiting Study Name: Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Condition:
  • Adult Fibrosarcoma
  • Alveolar Soft Part Sarcoma
  • Angiomatoid
    Date: 2014-07-01
    Interventions:
    • Drug: Doxorubicin Hydrochloride

Recruiting Study Name: Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus
Condition: Sporadic Angiomyolipomas (AMLs)
Date: 2015-08-20
Interventions: Drug: Everolimus 10 mg tablets
Recruiting Study Name: Sirolimus in Treating Patients With Angiomyolipoma of the Kidney
Condition: Nonmalignant Neoplasm
Date: 2005-08-02
Interventions: Drug: sirolimus
Not yet recruiting Study Name: LAM Pilot Study With Imatinib Mesylate
Condition: Lymphangioleiomyomatosis
Date: 2017-04-24
Interventions:
  • Drug: Imatinib Mesylate 400Mg Capsule

Recruiting Study Name: A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)
Condition: Lymphangioleiomyomatosis
Date: 2016-10-07
Interventions: Drug: Nintedanib Other Name: OFEV
Recruiting Study Name: Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis
Condition: Pulmonary Lymphangioleiomyomatosis
Date: 2016-03-31
Interventions: Drug: saracatinib Subjects will receive enough tablets for 90 days +/- 14 days at each visit. Subject wi
Next >>>